Cost of care of haemophilia with inhibitors

Haemophilia

Volumn 16, Issue 1, 2010, Pages

  Di Minno, M N ^a   Di Minno, G ^a,b   Di Capua, M ^a,b   Cerbone, A M ^b,c   Coppola, A ^c  

^a Reference Centre for Hemophilia and Thrombosis   (Italy)

^b Department of Clinical and Experimental Medicine ^*  (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cross utility analysis; Decision models; Haemophilia; Inhibitors; Pharmacoeconomy; Quality of life

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHROPATHY; BLEEDING; CHRONIC DISEASE; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEMARTHROSIS; HEMOPHILIA; HUMAN; MEDICAL PRACTICE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REPEATED DRUG DOSE; RESOURCE ALLOCATION; REVIEW; SINGLE DRUG DOSE; WESTERN HEMISPHERE;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FACTOR VIIA; HEALTH CARE COSTS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 73949143119     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02100.x     Document Type: Review

References (49)

1. DiMichele D, Lee CA, Hoots K, Berntorp E. Inhibitors to factor VIII - epidemiology and treatment. Textbook of Hemophilia 2005, 64-70. In, eds, Oxford, Blackwell Science
2. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-54.
3. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007, 13:65-8.
4. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005, 11:611-9.
5. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost-analysis from the Haemophilia Utilization Group Study. Haemophilia 2004, 10:63-70.
6. Negrini C, Daniele F, Mancuso ME, Rivolta GF, Tagliaferri A. Economic implications of treating patients with haemophilia and inhibitors: a systematic literature review [article in Italian]. Pharmacoeconomics Ital Res Articles 2006, 8:1-12.
7. Paisley S, Wight J, Currie E, Knight J. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003, 9:405-17.
8. Berntorp E, Shapiro A, Astermark J. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006, 12:1-7.
9. Rodriguez-Merchan EC, Hedner U, Heijnen L. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia 2008, 14:68-81.
10. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors Organization (UKHCDO). Br J Haematol 2000, 111:78-90.
11. Rubinger M, Rivard GE, Teitel J, Walker I. Suggestions for the management of factor VIII inhibitors. Haemophilia 2000, 6:52-9.
12. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study. Blood 2003, 102:2358-63.
13. Lyseng-Williamson KA, Plosker GL. Recombinant Factor VIIa (Eptacog Alfa). A pharmacoeconomic review of its use in haemophilia patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007, 25:1007-29.
14. Knight C, Danø AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 2009, 15:405-19.
15. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with inhibitors. Haemophilia 2003, 9:521-40.
16. Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999, 5:397-401.
17. Chang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. Haemophilia 1999, 5:247-52.
18. Bohn LR, Aledort LM, Putnam KG. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004, 10:63-8.
19. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high responding factor VIII and IX inhibitors. Haemophilia 2006, 12:74-80.
20. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001, 7:279-85.
21. Odayemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII and activated prothrombin complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting factor VIII and IX at a comprehensive care centre in the UK. J Med Econ 2002, 5:51-64.
22. Odayemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factor VIII and IX in the UK. J Med Econ 2002, 5:119-33.
23. Huth-Kuehne A, Lages P, Zimmermann R. The impact of rebleeds in cost modelling of treatment strategies in patients with haemophilia and inhibitors. Blood 2006, 108:90b. [Abstract]
24. Joshi AV, Stephens JM, Munro V. Pharmacoeconomic analysis of recombinant Factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in haemophilia patients with inhibitors. Curr Med Res Opin 2006, 22:23-31.
25. Dundar S, Zülfikar B, Kavakli K. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia with inhibitors in Turkey. J Med Econ 2005, 8:45-54.
26. Ozelo MC, Villaça PR, De Almeida JO. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007, 13:462-9.
27. Plyush O, Kopylov K, Zozulya N. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Russia. Paediatr Haematol Oncol Immunopathol 2006, 5:16-22.
28. Putnam KG, Bohn RL, Ewenstein BM. A cost minimization model for treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005, 11:261-9.
29. Steen-Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008, 99:1060-7.
30. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 γg kg-1-dose rFVIIa vs. standard 90 γg kg-1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14:287-94.
31. DiMichele DM, Hoots K, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007, 13:1-22.
32. Aledort LM, Kroner B, Mariani G. Hemophilia treatment. Immune tolerance induction: treatment duration analysis and economic considerations. Haematologica 2000, 85:83-5.
33. Mariani G, Kroner B. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001, 86:1186-93.
34. Auerswald M, von Depka Prondzinski M, Ehlken B. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004, 10:499-508.
35. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000, 96:1698-702.
36. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005, 11:11-17.
37. DiMichele D, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006, 4:2271-3.
38. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance:the RESIST study. Haemophilia 2007, 13:73-7.
39. Kreuz W, Ettingshausen CE, Auerswald G. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003, 88:EREP04.
40. Orsini F, Rotschild C, Beurrier P. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005, 90:1288-90.
41. Gringeri A, Musso R, Mazzucconi MG. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007, 13:373-9.
42. Kurth MA, DiMichele D, Sexauer C. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008, 14:50-5.
43. Greninger DA, Saint-Remy JM, Jacquemin M. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008, 14:295-302.
44. Astermark J, Morado M, Rocino A. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006, 12:363-71.
45. Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009, Epub ahead of print
46. Santagostino E, Mancuso ME, Rocino A. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005, 130:422-7.
47. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-54.
48. Briggs A, Gray A. Economics notes using cost effectiveness information. BMJ 2000, 320:246.
49. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med 2006, 62:2091-100.